Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
about
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosisTMC207: the first compound of a new class of potent anti-tuberculosis drugsCharacterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug developmentA Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-AnalysisDrug therapy in spinal tuberculosisLearning from the past for TB drug discovery in the futureCrystal structure of the yeast nicotinamidase Pnc1pStructural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamideNew insights into TB physiology suggest untapped therapeutic opportunitiesPrioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosisIdentification of functional differences in metabolic networks using comparative genomics and constraint-based modelsEthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targetspH-dependent pore-forming activity of OmpATb from Mycobacterium tuberculosis and characterization of the channel by peptidic dissectionIn vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosisEstablishment and validation of whole-cell based fluorescence assays to identify anti-mycobacterial compounds using the Acanthamoeba castellanii-Mycobacterium marinum host-pathogen systemWhole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from PakistanUnravelling the Secrets of Mycobacterial Cidality through the Lens of AntisenseMechanisms of Pyrazinamide Action and ResistanceNew antimycobacterial agents in the pre-clinical phase or beyond: recent advances in patent literature (2001-2016).Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan.Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosisLatent tuberculosis infection: myths, models, and molecular mechanismsUncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosisNovel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.Nicotinamidase/pyrazinamidase of Mycobacterium tuberculosis forms homo-dimers stabilized by disulfide bonds.Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infectionPyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase IA 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosisThe tuberculosis drug discovery and development pipeline and emerging drug targets.Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.
P2860
Q24609567-18C8F093-0918-45E1-BE2F-F73BF2D87898Q24632091-EE1F6536-1AEE-4DFD-AFC7-AC8C2B099168Q24681801-9789B755-3157-4082-8A19-3D2A064FB82AQ27011264-6F2B96F7-967B-4A11-8338-C8B5DEAE357CQ27022999-ADE3012C-3FC3-42FE-A93D-454D67C6D85EQ27485405-DF4ECC7D-4DE6-4B04-9703-32FC980CDAB1Q27644216-5E4C2D08-D666-4E4B-81EB-BFAFFE81E5B8Q27696223-09541716-D80F-4E71-B9C2-065C5C6F2A2BQ28388477-BBEE0D12-8D64-4889-8FAA-FFA3C0203EBBQ28469010-C88DF75D-2AC4-47DB-B683-12DFDE660A49Q28483888-12ADC56B-3ABC-4C9B-978F-622404FB00B1Q28486213-7299D595-9E21-4226-901E-EDF1193E3B17Q28486819-B821996F-592B-403D-A2AA-ED3113AB0E13Q28533382-98FEDB52-AAE3-4971-8619-F01EA6FF517CQ28539402-D0314285-9A78-4768-AC97-86F0AC979804Q28543682-40D64A9B-D9BC-4552-9C5F-75FD37AFD8CDQ28551800-ED694037-CBB2-4A41-A334-D8E880313087Q29304444-7FC0784E-3947-4BB5-8B05-539326D4EBCBQ30243915-4EA61E1D-C4C9-4D97-BCEC-A6391728AA99Q30373724-5A23CFFC-D204-4253-8991-662CD26457E9Q33667486-0E7C6F4A-C5B5-4E46-8577-CE58B0FA124EQ33704769-B43DA4E2-A02D-449F-9A9F-09444DB3E99AQ33752491-D8A53E64-793C-4534-A5B9-3254A789DC25Q34017127-1299A0A5-361D-4E84-9259-C1EC4AF606D5Q34113610-8237D4A4-6D87-4A45-8260-3BEC823F9BB0Q34297816-D5AA3C74-BBCA-4EF4-A864-831725FD1818Q34494098-4E9E1A43-9BBF-4993-AFFE-8ED1F285CCC2Q34596427-EB863772-BA8B-4BCB-8E44-0FEB759FF33BQ34644335-6F6EF6EC-CD45-4F0D-AA6B-2E507C315B79Q34708437-CCB9F16C-E3FE-4892-BEC0-23D809FD2B9DQ34737913-C2ABBE7D-B663-4628-AC5A-CAA83EB2FBE1Q34918855-2BEB23E3-BF95-4904-9319-5B07C06A888BQ34974987-C6A07CF2-EA02-480B-907C-D2AB654A7D4EQ34981779-887130A1-A90F-4569-B54C-5ABC68A380D8Q35168078-A2525AD7-61F7-4EA6-AE3B-E9AA3E8AB5CFQ35617587-090B599F-F159-48A1-89A7-1C5246D13F6BQ35647811-EE36FCF6-C4E9-475C-BEED-055CF7888515Q35664209-D075FD8C-2C0C-40F0-B177-332A0A3B607DQ35689060-F6588713-D2D2-499D-9DD7-6F53DEE2A386Q35718261-EF7EBC19-61AB-4215-BBD6-A05A109C12E6
P2860
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@ast
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@en
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@nl
type
label
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@ast
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@en
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@nl
prefLabel
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@ast
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@en
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@nl
P2093
P356
P1476
Mode of action of pyrazinamide ...... energetics by pyrazinoic acid.
@en
P2093
Angelo Scorpio
Mary Margaret Wade
Ying Zhang
Zhonghe Sun
P304
P356
10.1093/JAC/DKG446
P407
P577
2003-10-16T00:00:00Z